# 藥動
## 給藥 Administration
- 慢速 IV $\rightarrow$ 治療全身感染
- 口服 $\rightarrow$ 壞死性腸炎 enterocolitis
## 分布 Distribution
## 代謝 Metabolism
- 半衰期 6-10 hrs
## 排泄 Excretion 
- 尿液排出
# 應用
- 用於嚴重 G (+) 
	- endocarditis 心內膜炎
	- meningitis 腦膜炎
	- sepsis 敗血症
	- MRSA, MRSE, hemolytic Strep
	- Enterococcus faecalis & faecium 
	- Listeria species 
	- Actinomyces
- 與 [[Gentamicin 紫菌素]] 協同治療 enterococcal endocarditis (心內膜炎)
- IV 用於人工瓣膜、導管感染
	-  Staphylococci & Corynebacterium (diphtheroids, 類白喉)
- 口服用於抗生素相關性腸炎
	- Clostridium difficile & Staphylococci 
- 對 G-(-) 無活性
	- 除了 Neisseria spp
# 副作用
- 高劑量注射造成 anaphylactoid reactions 類過敏反應
	- hypotension, wheezing, dyspnea 呼吸困難, urticaria 蕁麻疹, and pruritus 瘙癢症
- nephrotoxicity 腎毒性 and auditory nerve damage, phlebitis 靜脈炎
- Ototoxicity 聽毒性
- Red-man syndrome
	- drug rash (histamine release)
# 藥物交互作用
# 抗藥性
- mutation in pentapeptide chain of cell wall building block
	- Terminal D-alanine replaced by D-lactate
	- Peptide link replaced by ester link
	- Loss of NH (HBD)
	- Weakens binding affinity of vancomycin with ‘tail’
	- Lactate acts as a leaving group in cell wall synthesis
- Staphylococcus aureus (VRSA)
- enterococci (VRE)

# 藥化
## MOA
- 結合 D-alanine-D-alanine terminals of the uridine diphosphate-N-acetyl-muramyl peptides $\rightarrow$ 抑制 transglycosidase $\rightarrow$ 抑制 mucopeptide 生合成
- 
## SAR
- 結構
	- a glycosylated hexapeptide chain
	- pyrogallol ester linkage to glucose and vancosamine
		- ![[Pasted image 20230503001757.png|100]]![[Pasted image 20230503002126.png|100]]
	- five benzene ring
- 
![[Chemical-structure-of-vancomycin-The-disaccharide-composed-of-vancosamine-and-glucose.png|300]]